Filing Overview
Registrant: Jupiter Wellness, Inc. (trading symbols JUPW and JUPWW), despite request metadata identifying BONK, INC. The Form 8-K reports an event dated September 3, 2021; the filing was signed September 8, 2021.
Business Context and Reporting Period
The filing concerns an amendment to the company’s endorsement arrangement with Tee-2-Green Enterprises Limited relating to golfer Ernie Els and the company’s CaniSun, CaniSkin, and CaniDermRX product lines. It is not a periodic financial report and does not present results for a fiscal quarter or year.
Material Agreement and Financial Terms
- The original three-year endorsement agreement was extended by two years.
- The amended agreement now terminates at midnight on November 25, 2025.
- Jupiter Wellness will issue Tee-2-Green 60,000 additional shares of restricted common stock.
- The company will pay $75,000 in each of years four and five of the agreement, for total additional stated cash payments of $150,000.
- The equity issuance is reported under Item 3.02 as an unregistered sale of equity securities.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, cash balances, liquidity measures, or other operating financial metrics. It also does not state the value of the 60,000 restricted shares or describe the accounting treatment of the endorsement costs.
Management Commentary, Outlook, and Risks
The company announced the agreement extension through a press release furnished as Exhibit 99.1. The filing provides no quantitative operating guidance or broader financial outlook. Key considerations include the cash commitment through 2025, potential dilution from the restricted stock issuance, and the dependence of the arrangement’s value on the effectiveness of the Ernie Els endorsement in promoting the covered products.
Investor Verification Items
- Confirm the identity of the registrant, because the supplied metadata names BONK, INC. while the filing names Jupiter Wellness, Inc.
- Review Exhibit 10.1 for the complete amended agreement, including vesting, transfer restrictions, termination provisions, and any additional obligations.
- Verify the number of shares outstanding and the potential dilution represented by the 60,000 restricted shares.
- Assess whether the $150,000 cash commitment is incremental to amounts payable under the original agreement.
- Review subsequent filings for issuance of the shares, payments made, agreement performance, and any impairment or expense recognition.